Gastrointestinal contrast agent developer E-Z-EM of Westbury, NY, this month appointed David Wills as general manager for its U.K. subsidiary, E-Z-EM Ltd. of London. Wills plans to focus on bolstering the company’s share in the U.K. barium sulfate
Gastrointestinal contrast agent developer E-Z-EM of Westbury, NY, this month appointed David Wills as general manager for its U.K. subsidiary, E-Z-EM Ltd. of London. Wills plans to focus on bolstering the companys share in the U.K. barium sulfate contrast market. He comes to E-Z-EM from Medtronic U.K. Ltd., where he served as business development manager for that firms peripheral vascular division. Wills brings 16 years of medical device sales experience to his new post.
Multicenter Study Identifies Key Factors Associated with Mammogram-Occult Ipsilateral Breast Cancer
October 9th 2024A symptomatic first breast cancer diagnosis, prevailing breast density at a second breast cancer diagnosis and trabecular thickening on surveillance mammography were linked to mammogram-occult ipsilateral breast cancer, according to new research.
Can Innovations with AI Help Address the Impact of Staffing Shortages on Radiology Workflow?
October 7th 2024While staffing shortages in radiology continue to persist after the COVID-19 pandemic, current and emerging innovations powered by artificial intelligence (AI) may help facilities navigate these challenges and mitigate rising costs of health care.